Global Turner Syndrome Outlook 2025, Forecast To 2034
26 Mar, 2025
How Has the Turner Syndrome Market Size Evolved in Recent Years?
The turner syndrome market has seen considerable growth due to a variety of factors.
• In the past few years, the market size for Turner Syndrome has witnessed significant growth. It is projected to rise from $2.36 billion in 2024 to $2.55 billion in 2025, showcasing a compound annual growth rate (CAGR) of 8.0%.
Factors such as heightened awareness about women's health, increased spending on healthcare, the expansion of the healthcare sector, improved understanding and early detection of Turner Syndrome, and initiatives to raise public awareness have contributed to this historical growth period.
What Are The Predictions for The Turner Syndrome Market in the Coming Years?
The turner syndrome market is expected to maintain its strong growth trajectory in upcoming years.
• The market for Turner Syndrome is projected to experience significant expansion over the next couple of years. With a compound annual growth rate (CAGR) of 7.7%, it's predicted to reach $3.42 billion by 2029.
This forthcoming growth during the forecast era can be accredited to various factors such as escalating instances of x chromosome structural anomalies, the extensive use of estrogen replacement therapy, the rising application of chromosomal microarray analysis (CMA) for disease diagnosis, an increasing female population, and enhanced research and development efforts. The period of forecast also points towards major trends like the adoption of innovative technologies, product introductions, advancements in growth hormone treatment, an increased need for hormonal treatments, and the crafting of new therapies.
Which Drivers Are Accelerating Growth In The Turner Syndrome Market?
The growth of the Turner syndrome market is anticipated to be fueled by the expanding female population. The female population refers to the total number of women residing in a specific region or globally at a particular time. The surge in female population results from factors like prolonged life expectancy, enhanced healthcare, and demographic shifts. Treatment for Turner syndrome aids the female population by offering growth hormone therapy to heighten stature, estrogen replacement to stimulate puberty and preserve bone health, and extensive medical care to tackle associated conditions, thus promoting physical development, reproductive health, and overall well-being. For example, in March 2024, based on data from the Census Bureau, a US government agency, the female population in the United States was recorded at approximately 168 million as of July 2022. Additionally, there were around 1.9 million more females aged 85 and above. Furthermore, based on a report published in December 2022 by CEIC Data, a UK-based financial service firm, the count of females between the ages of 15-64 was noted to be 2,951,856 in 2022, depicting a rise from 2,940,645 in 2021. Consequently, the burgeoning female population is driving the expansion of the Turner syndrome market.
What Are The Core Segments Of The Global Turner Syndrome Market?
The turner syndrome market covered in this report is segmented –
1) By Type: Classical Turner Syndrome, Mosaic Turner syndrome
2) By Therapy Type: Growth Hormone Therapy, Estrogen And Progesteron, Replacement Therapy, Other Therapy Types
3) By Drug Type: Norditropin, Oxandrolone, Humatrope, Somatropin, Oxandrin, Genotropin, Nutropin, Zomacton
4) By End-User: Hospitals, Homecare, Specialty Clinics, Surgical Centres, Other End-Users
Subsegments:
1) By Classical Turner Syndrome: Complete Monosomy X, X Chromosome Deletion
2) By Mosaic Turner Syndrome: Mosaicism With 45,X/46,XX Karyotype, Mosaicism With 45,X/46,XY Karyotype
What Trends Are Reshaping The Future Of The Turner Syndrome Market?
Key players in the turner syndrome market, such as Ascendis Pharma A/S, are emphasizing on clinical trials to develop new, ground-breaking products like pediatric growth hormone drugs. These medications are designed to stimulate and enhance growth, helping to improve height outcomes and overall development in children suffering from growth hormone deficiencies or growth-related disorders. Synthetic or recombinant versions of these hormones are utilized to promote growth and development in children with growth hormone deficiency (GHD) or other medical conditions that affect height and growth. For example, in December 2024, Ascendis Pharma A/S, located in Denmark, reported positive outcomes from the Phase 2 New InsiGHTS trial of TransCon hGH (lonapegsomatropin) on Turner syndrome-affected children. The study included 49 prepubertal children between the ages of 1-10 years diagnosed with Turner syndrome. TransCon hGH showed improved growth in all three starting dose cohorts, equivalent to the daily administration of somatropin. The success of this trial suggests a promising market expansion for TransCon hGH in treating Turner syndrome, offering safety and efficiency levels on par with daily treatment regimes.
Who Are the Key Players In The Turner Syndrome Market?
Major companies operating in the turner syndrome market are:
• Pfizer Inc.
• Sanofi SA
• AstraZeneca Plc
• Abbott Laboratories
• Novartis AG
• LG Chem Ltd.
• Eli Lilly and Company
• Novo Nordisk
• Merck KGaA
• Teva Pharmaceutical Industries Ltd.
• Sandoz International GmbH
• Genentech Inc.
• Ipsen Pharma
• Ferring Pharmaceutical
• BioMarin Pharmaceutical Inc.
• United Imaging Healthcare Co. Ltd.
• Daewoong Pharmaceutical Co. Ltd.
• OPKO Health Inc.
• Hanmi Pharmaceutical Co. Ltd.
• Dong-A ST Co. Ltd.
• GeneScience Pharmaceuticals Co. Ltd.
• Ascendis Pharma
• AnkeBio Co. Ltd.
• Biopartners Inc.
• Kexing Biopharm Co. Ltd.
What Are The Regional Insights Into The Turner Syndrome Market?
North America was the largest region in the turner syndrome market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the turner syndrome market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.